Citing misleading advertisements, the Ayurveda and Unani Licensing Authority, Uttarakhand has asked Divya Pharmacy, which makes Patanjali products, to stop the production of five medicines.
In protest, yoga guru Baba Ramdev has accused an ‘anti-Ayurveda drug mafia’ of conspiring. The company said that it has not received a copy of the order given in the newspaper report, but the involvement of the “anti-Ayurveda drug mafia is clear”.
In a statement, the company said, “All the products and medicines made by Patanjali are made in Ayurveda tradition with the help of more than 500 scientists, with the highest research and quality, following all the statutory procedures and the prescribed standards, meeting the international standards. goes.”
“The letter which was written in a conspiracy and circulated in the media on 9.11.2022 in a manner sponsored by Ayurveda and Unani Seva Uttarakhand has not been made available to Patanjali Sansthan in any form so far.”
The company further said, “Either the department should rectify its mistake and take appropriate action against the person involved in this conspiracy, otherwise the institution will take legal action to punish the persons responsible for this conspiracy including compensation for the institutional damage caused to Patanjali.”
Several newspaper reports on Thursday said the Uttarakhand authority has asked Ramdev’s Patanjali Ayurved to stop manufacturing five products the company has promoted to treat blood pressure, diabetes, goiter, glaucoma and high cholesterol. as done.
According to a report, the Ayurveda and Unani Licensing Authority in Dehradun, Uttarakhand has directed Divya Pharmacy to stop production of Madhugrit, Igrit, Thyrogrit, BPgrit and Lipidome.
The order was issued by Dr GCS Jangpangi, Licensing Officer, Uttarakhand Ayurvedic and Unani Services and accused Patanjali of misleading advertisements.
The action is based on a complaint filed in July by Kerala-based ophthalmologist KV Babu. KV Babu had sent another complaint to the State Licensing Authority (SLA) via email on October 11.
